
Jonathan B Angel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8666190/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet, The, 2017, 390, 1499-1510.	13.7	391
2	Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. Journal of Neural Transmission, 2011, 118, 795-808.	2.8	230
3	Ritonavir and saquinavir combination therapy for the treatment of HIV infection. Aids, 1999, 13, 213-224.	2.2	176
4	CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. Aids, 2005, 19, 1473-1479.	2.2	173
5	Fertility Desires and Intentions of HIV-Positive Women of Reproductive Age in Ontario, Canada: A Cross-Sectional Study. PLoS ONE, 2009, 4, e7925.	2.5	131
6	Dexamethasone Inhibits IL-12p40 Production in Lipopolysaccharide-Stimulated Human Monocytic Cells by Down-Regulating the Activity of c-Jun N-Terminal Kinase, the Activation Protein-1, and NF-ήB Transcription Factors. Journal of Immunology, 2004, 172, 318-330.	0.8	121
7	Interleukin-7 Receptor Expression on CD8 + T Cells Is Reduced in HIV Infection and Partially Restored With Effective Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 454-457.	2.1	109
8	Development of Cervical Fat Pads Following Therapy with Human Immunodeficiency Virus Type 1 Protease Inhibitors. Clinical Infectious Diseases, 1998, 27, 65-67.	5.8	108
9	Decreased HIV-Associated T Cell Apoptosis by HIV Protease Inhibitors. AIDS Research and Human Retroviruses, 2000, 16, 559-567.	1.1	97
10	Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death and Differentiation, 1999, 6, 420-432.	11.2	94
11	Vaccine-Associated Measles Pneumonitis in an Adult with AIDS. Annals of Internal Medicine, 1998, 129, 104.	3.9	92
12	Clinical, hematologic, and immunologic effects of interleukin-10 in humans. Journal of Clinical Immunology, 1996, 16, 291-303.	3.8	85
13	Soluble IL-7Rα (sCD127) Inhibits IL-7 Activity and Is Increased in HIV Infection. Journal of Immunology, 2010, 184, 4679-4687.	0.8	84
14	IL-7 decreases IL-7 receptor (CD127) expression and induces the shedding of CD127 by human CD8+ T cells. International Immunology, 2007, 19, 1329-1339.	4.0	76
15	Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. Aids, 2002, 16, 1251-1256.	2.2	71
16	Reactivation of Hepatitis B Infection following Allogeneic Bone Marrow Transplantation in a Hepatitis B-Immune Patient: Case Report and Review of the Literature. Clinical Infectious Diseases, 2005, 41, 1277-1282.	5.8	71
17	Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatmentâ€Naive Subjects with HIVâ€I Infection. Journal of Infectious Diseases, 2008, 198, 1113-1122.	4.0	71
18	Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 31-38.	2.1	71

#	Article	IF	CITATIONS
19	IL-10 Regulation by HIV-Tat in Primary Human Monocytic Cells: Involvement of Calmodulin/Calmodulin-Dependent Protein Kinase-Activated p38 MAPK and Sp-1 and CREB-1 Transcription Factors. Journal of Immunology, 2007, 178, 798-807.	0.8	70
20	Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. PLoS ONE, 2016, 11, e0148231.	2.5	70
21	Acute phase responses and cytokine secretion in chronic fatigue syndrome. Journal of Clinical Immunology, 1999, 19, 414-421.	3.8	69
22	Effect of Antiretroviral Therapy and Viral Load on the Perceived Risk of HIV Transmission and the Need for Safer Sexual Practices. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 124-129.	0.3	68
23	Hepatotoxicity Associated with Antiretroviral Therapy Containing Dual versus Single Protease Inhibitors in Individuals Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus. Clinical Infectious Diseases, 2002, 34, 1259-1263.	5.8	66
24	Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. Aids, 2000, 14, 2467-2473.	2.2	65
25	Salivary Detection of COVID-19. Annals of Internal Medicine, 2021, 174, 131-133.	3.9	64
26	Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. Journal of Clinical Immunology, 1997, 17, 253-261.	3.8	59
27	Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/μl when viral replication is suppressed. Aids, 2007, 21, 1711-1715.	2.2	48
28	Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α inhibitor use. Diagnostic Microbiology and Infectious Disease, 2005, 53, 233-238.	1.8	47
29	Intracellular HIV-Tat Expression Induces IL-10 Synthesis by the CREB-1 Transcription Factor through Ser133Phosphorylation and Its Regulation by the ERK1/2 MAPK in Human Monocytic Cells. Journal of Biological Chemistry, 2006, 281, 31647-31658.	3.4	46
30	LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. EBioMedicine, 2021, 65, 103270.	6.1	46
31	Protease inhibitors and adipocyte differentiation in cell culture. Lancet, The, 1998, 352, 1032.	13.7	45
32	Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Aids, 2000, 14, 387-395.	2.2	42
33	Development and Validation of the HIV Medication Readiness Scale. Assessment, 2007, 14, 408-416.	3.1	42
34	A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. Aids, 2011, 25, 731-739.	2.2	41
35	Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease. Frontiers in Immunology, 2019, 10, 1926.	4.8	41
36	Altruism motivates participation in a therapeutic HIV vaccine trial (CTN 173). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 1403-1409.	1.2	40

#	Article	IF	CITATIONS
37	External Quality Assessment of <i>HLA-B*5701</i> Reporting: An International Multicentre Survey. Antiviral Therapy, 2007, 12, 1027-1032.	1.0	40
38	Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. BMJ Open, 2019, 9, e028444.	1.9	39
39	IFN-γ-induced IL-27 and IL-27p28 expression are differentially regulated through JNK MAPK and PI3K pathways independent of Jak/STAT in human monocytic cells. Immunobiology, 2014, 219, 1-8.	1.9	37
40	Impairment of the type I interferon response by HIV-1: Potential targets for HIV eradication. Cytokine and Growth Factor Reviews, 2017, 37, 1-16.	7.2	34
41	Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. Aids, 1995, 9, 1137-1144.	2.2	33
42	The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 777-784.	1.2	32
43	Proteomic Characterization of Pig Sperm Anterior Head Plasma Membrane Reveals Roles of Acrosomal Proteins in ZP3 Binding. Journal of Cellular Physiology, 2015, 230, 449-463.	4.1	32
44	The influence of HIV on CD127 expression and its potential implications for IL-7 therapy. Seminars in Immunology, 2012, 24, 231-240.	5.6	31
45	Cyclosporin A and FK506 Inhibit IL-12p40 Production through the Calmodulin/Calmodulin-dependent Protein Kinase-activated Phosphoinositide 3-Kinase in Lipopolysaccharide-stimulated Human Monocytic Cells. Journal of Biological Chemistry, 2007, 282, 13351-13362.	3.4	29
46	An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. Aids, 2001, 15, 417-419.	2.2	28
47	CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. Journal of Immune Based Therapies and Vaccines, 2008, 6, 4.	2.4	26
48	Discontinuation of Pneumocystis jirovecii Pneumonia Prophylaxis with CD4 Count <200 Cells/µL and Virologic Suppression: A Systematic Review. PLoS ONE, 2011, 6, e28570.	2.5	26
49	IL-7-dependent STAT-5 activation and CD8+ T cell proliferation are impaired in HIV infection. Journal of Leukocyte Biology, 2010, 89, 499-506.	3.3	25
50	Hormonal influences on stress-induced neutrophil mobilization in health and chronic fatigue syndrome. Journal of Clinical Immunology, 1998, 18, 291-298.	3.8	24
51	A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. Aids, 2000, 14, 2503-2508.	2.2	23
52	Cardiovascular complications of Salmonella enteritidis infection. Canadian Journal of Cardiology, 2010, 26, e323-e325.	1.7	23
53	Jak/STAT and PI3K signaling pathways have both common and distinct roles in IL-7-mediated activities in human CD8+ T cells. Journal of Leukocyte Biology, 2013, 95, 117-127.	3.3	23
54	IL-23 signaling in Th17 cells is inhibited by HIV infection and is not restored by HAART: Implications for persistent immune activation. PLoS ONE, 2017, 12, e0186823.	2.5	23

#	Article	IF	CITATIONS
55	Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. Journal of the International AIDS Society, 2015, 18, 20497.	3.0	22
56	Remodeling of the plasma membrane in preparation for sperm-egg recognition: roles of acrosomal proteins. Asian Journal of Andrology, 2015, 17, 574.	1.6	22
57	Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. Aids, 2007, 21, 71-76.	2.2	21
58	Patients with Discordant Responses to Antiretroviral Therapy Have Impaired Killing of HIV-Infected T Cells. PLoS Pathogens, 2010, 6, e1001213.	4.7	21
59	HIV Knowledge Among Canadian-Born and Sub-Saharan African-Born Patients Living with HIV. Journal of Immigrant and Minority Health, 2012, 14, 132-139.	1.6	21
60	Sustained Suppression of Plasma HIV RNA Is Associated with an Increase in the Production of Mitogen-Induced MIP-1alpha and MIP-1beta. AIDS Research and Human Retroviruses, 1999, 15, 1073-1077.	1.1	20
61	Development of Kaposi's Sarcoma Despite Sustained Suppression of HIV Plasma Viremia. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 209.	2.1	20
62	Differential Regulation of CXCR4 and CCR5 Expression by Interleukin (IL)-4 and IL-13 Is Associated with Inhibition of Chemotaxis and Human Immunodeficiency Virus (HIV) Type 1 Replication But Not HIV Entry into Human Monocytes. Viral Immunology, 2006, 19, 409-423.	1.3	20
63	Development of Kaposi's Sarcoma Despite Sustained Suppression of HIV Plasma Viremia. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 209.	2.1	19
64	cIAP1/2–TRAF2–SHP-1–Src–MyD88 Complex Regulates Lipopolysaccharide-Induced IL-27 Production through NF-κB Activation in Human Macrophages. Journal of Immunology, 2018, 200, 1593-1606.	0.8	19
65	Getting to the Heart of the Matter: A Review of Drug Interactions Between HIV Antiretrovirals and Cardiology Medications. Canadian Journal of Cardiology, 2019, 35, 326-340.	1.7	19
66	Lentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy and Neuroimmune Activation. MBio, 2021, 12, e0278421.	4.1	19
67	Interleukinâ€7 enhances memory CD8 ⁺ Tâ€cell recall responses in health but its activity is impaired in human immunodeficiency virus infection. Immunology, 2010, 131, 525-536.	4.4	18
68	Circulating Endothelial Progenitor Cell Levels Are Not Reduced in HIV-Infected Men. Journal of Infectious Diseases, 2012, 205, 713-717.	4.0	18
69	Interleukinâ€4 downregulates CD127 expression and activity on human thymocytes and mature CD8 + T cells. European Journal of Immunology, 2010, 40, 1396-1407.	2.9	17
70	Complexed soluble IL-7 receptor α and IL-7 increase IL-7-mediated proliferation and viability of CD8+ T-cells in vitro. Cellular Immunology, 2015, 293, 122-125.	3.0	17
71	Self-Reported Preconception Care of HIV-Positive Women of Reproductive Potential. Journal of the International Association of Providers of AIDS Care, 2014, 13, 424-433.	1.5	16
72	Type I interferon responses are impaired in latently HIV infected cells. Retrovirology, 2016, 13, 66.	2.0	16

#	Article	IF	CITATIONS
73	Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and TÂcell immune response against SARS-CoV-2 infection. Molecular Therapy, 2022, 30, 1885-1896.	8.2	16
74	Long-Term Follow-up of a Cohort of HIV-Infected Patients Who Discontinued Maintenance Therapy for Cytomegalovirus Retinitis. HIV Clinical Trials, 2006, 7, 1-9.	2.0	15
75	IL-2 receptor chain cytokines differentially regulate human CD8+CD127+ and CD8+CD127- T cell division and susceptibility to apoptosis. International Immunology, 2009, 21, 29-42.	4.0	15
76	TLR-4 Agonist Induces IFN-γ Production Selectively in Proinflammatory Human M1 Macrophages through the PI3K-mTOR– and JNK-MAPK–Activated p70S6K Pathway. Journal of Immunology, 2021, 207, 2310-2324.	0.8	15
77	Circulating endothelial progenitor cells in HIV infection: A systematic review. Trends in Cardiovascular Medicine, 2013, 23, 192-200.	4.9	14
78	Antimicrobial peptide LL-37 and its truncated forms, GI-20 and GF-17, exert spermicidal effects and microbicidal activity against Neisseria gonorrhoeae. Human Reproduction, 2018, 33, 2175-2183.	0.9	14
79	Active cellular infection of myeloid cells is required for HIV-1-mediated suppression of interleukin-12 p40 expression. Cellular Immunology, 2002, 215, 120-132.	3.0	13
80	Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection. Journal of Immune Based Therapies and Vaccines, 2005, 3, 3.	2.4	13
81	Development of a Quantitative Bead Capture Assay for Soluble IL-7 Receptor Alpha in Human Plasma. PLoS ONE, 2009, 4, e6690.	2.5	13
82	Medical Assistance in Death as a Unique Opportunity to Advance Human Immunodeficiency Virus Cure Research. Clinical Infectious Diseases, 2019, 69, 1063-1067.	5.8	13
83	Short Communication: Human Immunodeficiency Virus Rebound in Blood and Seminal Plasma Following Discontinuation of Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2013, 29, 266-269.	1.1	12
84	Nef Protein of Human Immunodeficiency Virus and Lipopolysaccharide Induce Expression of CD14 on Human Monocytes through Differential Utilization of Interleukin-10. Vaccine Journal, 2002, 9, 1212-1221.	3.1	11
85	Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo. Frontiers in Bioscience - Landmark, 2004, 9, 338.	3.0	11
86	The Efficacy of Calcium Carbonate in the Treatment of Protease Inhibitor-Induced Persistent Diarrhea in HIV-Infected Patients. HIV Clinical Trials, 2004, 5, 19-24.	2.0	11
87	Optimization of culture and storage conditions for an in vitro system to evaluate thymocyte phenotype and function. Journal of Immunological Methods, 2006, 312, 157-166.	1.4	10
88	Early Changes in T-Cell Activation Predict Antiretroviral Success in Salvage Therapy of HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 149-155.	2.1	10
89	SMAC Mimetics as Therapeutic Agents in HIV Infection. Frontiers in Immunology, 2021, 12, 780400.	4.8	10
90	Virological evaluation of the â€~Ottawa case' indicates no evidence for HIV-1 superinfection. Aids, 2004, 18, 331-334.	2.2	9

#	Article	IF	CITATIONS
91	Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions. BMC Infectious Diseases, 2013, 13, 509.	2.9	9
92	Acute monoarthritis complicating therapy with indinavir. Aids, 2000, 14, 2064.	2.2	9
93	HIV-1 Nef Inhibits Lipopolysaccharide-induced IL-12p40 Expression by Inhibiting JNK-activated NFκB in Human Monocytic Cells. Journal of Biological Chemistry, 2009, 284, 7578-7587.	3.4	8
94	HIV infection of thymocytes inhibits IL-7 activity without altering CD127 expression. Retrovirology, 2011, 8, 72.	2.0	8
95	HIV and HIV-Tat inhibit LPS-induced IL-27 production in human macrophages by distinct intracellular signaling pathways. Journal of Leukocyte Biology, 2017, 102, 925-939.	3.3	8
96	HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine. Expert Opinion on Biological Therapy, 2016, 16, 953-966.	3.1	7
97	Sperm can act as vectors for HIVâ€1 transmission into vaginal and cervical epithelial cells. American Journal of Reproductive Immunology, 2019, 82, e13129.	1.2	7
98	IL-7-induced proliferation of peripheral Th17 cells is impaired in HAART-controlled HIV infection. Aids, 2019, 33, 985-991.	2.2	7
99	Selective killing of human M1 macrophages by Smac mimetics alone and M2 macrophages by Smac mimetics and caspase inhibition. Journal of Leukocyte Biology, 2021, 110, 693-710.	3.3	7
100	Association between radical cystectomy prophylactic antimicrobial regimen and postoperative infection. Canadian Urological Association Journal, 2021, 15, E644-E651.	0.6	7
101	Soluble Tumor Necrosis Factor Receptors Inhibit Phorbol Myristate Acetate and Cytokine-Induced HIV-1 Expression Chronically Infected U1 Cells. Journal of Acquired Immune Deficiency Syndromes, 1996, 11, 430-437.	0.3	7
102	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. BMJ Open, 2021, 11, e054208.	1.9	7
103	Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects. European Cytokine Network, 2007, 18, 49-58.	2.0	6
104	The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy). Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 122-128.	2.1	5
105	ILâ€7 induces sCD127 release and mCD127 downregulation in human CD8 ⁺ T cells by distinct yet overlapping mechanisms, both of which are impaired in HIV infection. European Journal of Immunology, 2020, 50, 1537-1549.	2.9	5
106	Soluble IL-7Rα/sCD127 in Health, Disease, and Its Potential Role as a Therapeutic Agent. ImmunoTargets and Therapy, 2021, Volume 10, 47-62.	5.8	5
107	Selective Induction of Cell Death in Human M1 Macrophages by Smac Mimetics Is Mediated by cIAP-2 and RIPK-1/3 through the Activation of mTORC. Journal of Immunology, 2021, 207, 2359-2373.	0.8	5
108	Soluble CD127 potentiates ILâ€7 activity in vivo in healthy mice. Immunity, Inflammation and Disease, 2021, 9, 1798-1808.	2.7	5

#	Article	IF	CITATIONS
109	Willingness of Older Canadians with HIV to Participate in HIV Cure Research Near and After the End of Life: A Mixed-Method Study. AIDS Research and Human Retroviruses, 2022, 38, 670-682.	1.1	5
110	Virologic and immunologic activity of PegIntron in HIV disease. Aids, 2009, 23, 2431-2438.	2.2	4
111	Disparate Regulation of LPS-Induced MAPK Signaling and IL-12p40 Expression Between Different Myeloid Cell Types with and without HIV Infection. Viral Immunology, 2010, 23, 17-28.	1.3	4
112	Expression of γâ€chain cytokine receptors on CD8 + T cells in HIV infection with a focus on ILâ€7Rα (CD127). Immunology and Cell Biology, 2012, 90, 379-387.	2.3	4
113	Exploring the Factors Considered by People Living with HIV and Their Partners during Preconception. Journal of the International Association of Providers of AIDS Care, 2017, 16, 239-246.	1.5	4
114	The Oncolytic Virus MG1 Targets and Eliminates Cells Latently Infected With HIV-1: Implications for an HIV Cure. Journal of Infectious Diseases, 2018, 217, 721-730.	4.0	4
115	Antimicrobial Peptide, LL-37, And Its Potential As An Anti-HIV Agent. Clinical and Investigative Medicine, 2021, 44, E64-71.	0.6	4
116	Role of RIPK1 in SMAC mimetics-induced apoptosis in primary human HIV-infected macrophages. Scientific Reports, 2021, 11, 22901.	3.3	4
117	Correction: IL-10 Regulation by HIV-Tat in Primary Human Monocytic Cells: Involvement of Calmodulin/Calmodulin-Dependent Protein Kinase-Activated p38 MAPK and Sp-1 and CREB-1 Transcription Factors. Journal of Immunology, 2012, 188, 3553-3553.	0.8	3
118	Optimizing the efficiency of therapeutic HIV vaccine trials: A case for CTN 173. Trials in Vaccinology, 2012, 1, 21-26.	1.2	3
119	Salivary testing of COVID-19: evaluation of serological testing following positive salivary results. BMC Infectious Diseases, 2021, 21, 410.	2.9	3
120	In Vitro HIV Type 1 Infection Indirectly Alters CD127 Expression on CD8+ T Cells. AIDS Research and Human Retroviruses, 2012, 28, 295-298.	1.1	2
121	Intravenous administration of Penicillin results in therapeutic intravitreal levels in chronic postoperative endophthalmitis. Journal of Ophthalmic Inflammation and Infection, 2021, 11, 1.	2.2	2
122	HIV-Infected Macrophages Are Infected and Killed by the Interferon-Sensitive Rhabdovirus MG1. Journal of Virology, 2021, 95, .	3.4	2
123	Characteristics of Hepatitis C Virus Infection in HIV-Infected People. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 157-163.	0.3	1
124	Canadian Consensus Guidelines for the Optimal Use of Etravirine in the Treatment of HIV-Infected Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e24-e34.	1.9	1
125	Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e67-e80.	1.9	1
126	Engagement of CD14 Sensitizes Primary Monocytes to IFN-γ to Produce IL-12/23p40 and IL-23 Through p38 Mitogen-Activated Protein Kinase and Independent of the Janus Kinase/Signal Transducers and Activators of Transcription Signaling. Journal of Interferon and Cytokine Research, 2013, 33, 434-445.	1.2	1

#	Article	IF	CITATIONS
127	Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. BMJ Open, 2020, 10, e041359.	1.9	1
128	Effects of Highly Active Antiretroviral Therapy and Immune Recovery on CD8+ T-Cell-Mediated Inhibition of HIV-1 Transcription. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 393-400.	2.1	0
129	Withdrawal of Pneumocystis prophylaxis: authors' reply. Aids, 2008, 22, 324.	2.2	0
130	IFN-Î ³ induces IL-23 expression in primary human monocytes via the p38 mitogen activated protein kinase independently of the JAK/STAT signalling. Cytokine, 2009, 48, 99-100.	3.2	0
131	ALVAC-HIV as a prophylactic and therapeutic vaccine: highlights from over a decade of clinical trials. Future Virology, 2011, 6, 1481-1492.	1.8	0
132	Cyclosporin A and FK506 inhibit IL-12p40 production through the calmodulin/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells Journal of Biological Chemistry, 2012, 287, 804.	3.4	0
133	HIV-1 Nef inhibits lipopolysaccharide-induced IL-12p40 expression by inhibiting JNK-activated NFκB in human monocytic cells Journal of Biological Chemistry, 2012, 287, 804.	3.4	0
134	Surreptitious Antiretroviral Use as an Explanation for Apparent Elite HIV Control. AIDS Patient Care and STDs, 2012, 26, 645-646.	2.5	0
135	Introduction to the Special Issue: HIV Evasion of the Antiviral Response. Cytokine and Growth Factor Reviews, 2018, 40, 1-2.	7.2	0
136	Beau's lines with onychomadesis in convalescence of invasive pneumococcal disease. Oxford Medical Case Reports, 2019, 2019, omz098.	0.4	0
137	Identification of novel genes involved in apoptosis of HIV-infected macrophages using unbiased genome-wide screening. BMC Infectious Diseases, 2021, 21, 655.	2.9	0
138	Association of the Frequency of Respiratory Illness in Early Childhood with a Change in the Distribution of Blood Lymphocyte Subpopulations. Allergy, Asthma and Clinical Immunology, 2005, 01, 135.	2.0	0
139	HIV Cure Research: An example of successful advocacy by scientists for science. Clinical and Investigative Medicine, 2018, 41, 14-16.	0.6	0
140	Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. BMJ Open, 2020, 10, e041359.	1.9	0